Why the study?
Does oral magnesium therapy improve endothelial function and exercise tolerance in patients with stable coronary artery disease?
Population
50 stable coronary artery disease patients
Comparison
Oral magnesium 30 mmol/d for 6 months vs Matching placebo for 6 months
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
6 months
Key result
Oral magnesium therapy for 6 months significantly improved postintervention flow-mediated vasodilation (15.5% vs 4.4%) and exercise tolerance (9.3 vs 7.3 minutes, P=0.05) in stable CAD patients.
Authors
Loading...
Supports oral magnesium in stable CAD; extends prior data with RCT confirmation of endothelial and exercise benefits.
RCT (n=50)
Double-blind
randomized
Does oral magnesium therapy improve endothelial function and exercise tolerance in patients with stable coronary artery disease?
Absolute Event Rate: 15.5% vs 4.4%
Oral magnesium therapy for 6 months significantly improves brachial artery endothelial function and exercise tolerance in patients with stable coronary artery disease.
Shechter et al. (2000) conducted an RCT in stable coronary artery disease (CAD) (n=50). Magnesium vs. Placebo was evaluated on postintervention endothelium-dependent brachial artery flow-mediated vasodilation (FMD). Oral magnesium therapy for 6 months significantly improved postintervention flow-mediated vasodilation (15.5% vs 4.4%) and exercise tolerance (9.3 vs 7.3 minutes, P=0.05) in stable CAD patients.